Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: Twelve-Month Results of a Prospective Randomized Study

Wenyi Tang#1,2,3, Jingli Guo#4, Gezhi Xu1,2,3, Wei Liu*, Qing Chang*1,2,3

1Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai, China
2Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, China
3NHC Key Laboratory of Myopia (Fudan University); Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China
4Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

# Wenyi Tang and Jingli contributed equally to the work.

*Correspondence: Qing Chang, PhD, Department of Ophthalmology, Eye and ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031, China, E-mail: qngchang@aliyun.com. Phone:86-21-64377134.

Or Wei Liu, PhD, Department of Ophthalmology, Eye and ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031, China, E-mail: Bfgt2020@163.com. Phone:86-21-64377134.
**Figure S1.** Flowchart showing patient randomisation and study completion in the 3+PRN and 1+PRN groups. N, number of patients; PRN, pro re nata
**Table S1.** Ocular Adverse Events in Patients with BRVO According to Treatment Regimen (3+PRN or 1+PRN)

|                     | 3+PRN (n = 35) | 1+PRN (n = 34) | P    |
|---------------------|----------------|----------------|------|
| Conjunctival haemorrhage | 3 (8.6)        | 3 (8.8)        | -    |
| Eye pain            | 2 (5.7)        | 1 (2.9)        | -    |
| Foreign body sensation | 2 (5.7)        | 1 (2.9)        | -    |
| IOP transiently increased | 1 (2.9)        | 1 (2.9)        | -    |
| Vitreous floaters   | 1 (2.9)        | 1 (2.9)        | -    |
| Total (%)           | 9 (25.7)       | 7 (20.6)       | 0.77 |

*BRVO* branch retinal vein occlusion, *PRN* pro re nata, *IOP* intraocular pressure